Axsome Therapeutics (NASDAQ:AXSM) primarily discovers, develops, and exclusively commercializes innovative medical treatments targeting numerous central nervous system disorders domestically. It formally initiated an extensive late-stage clinical trial evaluating solriamfetol as a targeted treatment for pediatric attention deficit hyperactivity disorder, and the U.S. Food and Drug Administration officially accepted its newly submitted New Drug Application for cataplexy in narcolepsy candidate AXS-12. Moderna (NASDAQ:MRNA) researches, develops, and globally commercializes diverse therapeutic applications and preventive medicines utilizing its proprietary messenger RNA technology.
CryptoAlerta — análise de criptomoedas e mercado em tempo real